Sam Brusco, Associate Editor01.24.23
Clinical decision support software firm Etiometry has gained U.S. Food and Drug Administration (FDA) clearance for its IDO2 Index.
The IDO2 Index is the company’s first FDA-cleared index for U.S. adults and follows Health Canada and CE mark approvals achieved last year. It lets critical care teams have access to risk analytics that alert them to patients likely experiencing inadequate oxygen delivery. Clinicians can then take action to prevent complications related to hypoxic conditions.
The Etiometry platform was first developed to help ICUs continuously aggregate data generated by high-acuity patients and display it to help avoid missing meaningful events. Its proprietary models of human physiology interprets patient-generated data for individual risk assessments to call attention to potential adverse patient states.
“Critical care settings are innately stressful. Using technology to centralize information and analytics on a single screen eliminates burdensome manual tasks. It allows clinicians to make data-driven decisions more efficiently—which is better for clinicians and patient care,” Etiometry’s CEO Shane Cooke told the press.
Etiometry has compiled a comprehensive database of over 150 million hours of patient physiologic signals, fueling algorithm enhancements and new developments. The IDO2 Index expansion into adult U.S. patients brings the company’s FDA clearances to eight. It follows the FDA clearance of two new algorithms for pediatric patients in 2022: Acidemia Index and HLA Index.
“With each iteration, Etiometry is scaling our technology to detect more pathways of patient deterioration, further strengthening the platform’s safety net for clinicians caring for critically ill patients,” said Dimitar Baronov, Etiometry’s co-founder and CTO. “This is what drives us. In fact, we are in the midst of developing our next-generation technology that identifies the etiologies of inadequate oxygenation, hence our company’s name: Etiometry.”
The IDO2 Index is the company’s first FDA-cleared index for U.S. adults and follows Health Canada and CE mark approvals achieved last year. It lets critical care teams have access to risk analytics that alert them to patients likely experiencing inadequate oxygen delivery. Clinicians can then take action to prevent complications related to hypoxic conditions.
The Etiometry platform was first developed to help ICUs continuously aggregate data generated by high-acuity patients and display it to help avoid missing meaningful events. Its proprietary models of human physiology interprets patient-generated data for individual risk assessments to call attention to potential adverse patient states.
“Critical care settings are innately stressful. Using technology to centralize information and analytics on a single screen eliminates burdensome manual tasks. It allows clinicians to make data-driven decisions more efficiently—which is better for clinicians and patient care,” Etiometry’s CEO Shane Cooke told the press.
Etiometry has compiled a comprehensive database of over 150 million hours of patient physiologic signals, fueling algorithm enhancements and new developments. The IDO2 Index expansion into adult U.S. patients brings the company’s FDA clearances to eight. It follows the FDA clearance of two new algorithms for pediatric patients in 2022: Acidemia Index and HLA Index.
“With each iteration, Etiometry is scaling our technology to detect more pathways of patient deterioration, further strengthening the platform’s safety net for clinicians caring for critically ill patients,” said Dimitar Baronov, Etiometry’s co-founder and CTO. “This is what drives us. In fact, we are in the midst of developing our next-generation technology that identifies the etiologies of inadequate oxygenation, hence our company’s name: Etiometry.”